Showing 4401-4410 of 10519 results for "".
- Dermatologist Harold Lancer and Ryan Seacrest Collaborate on Male Skincare Linehttps://practicaldermatology.com/news/dermatologist-harold-lancer-and-ryan-seacrest-collaborate-on-male-skincare-line/2458814/Dr. Harold Lancer and radio personality, television host and producer Ryan Seacrest have revealed an exclusive partnership in the burgeoning men's grooming category. They plan to launch a men's skincare line late in 2016. This pairing combines Dr. Lan
- Novan Appoints Chief Financial Officer and Chief Commercial Officer to Leadership Teamhttps://practicaldermatology.com/news/novan-appoints-chief-financial-officer-and-chief-commercial-officer-to-leadership-team/2458851/Novan Therapeutics appointed two new executives from the dermatology industry to the company's leadership team. Richard Peterson has joined the company as Chief Financial Officer and Brian Johnson as Chief Commercial Officer. Mr. Peterson will be responsible for the company's financi
- Murad Partners with AAD to Launch Shade America Programhttps://practicaldermatology.com/news/murad-partners-with-aad-to-launch-shade-america-program/2458951/Murad, Inc. partnered with the American Academy of Dermatology (AAD) to launch Shade America, a new program that will build shade structures in parks and playgrounds across America to provide shade from the sun’s harmful rays. Through the Shade America program, Murad’s goal is to prov
- DermaSensor’s Skin Cancer Device May Help Primary Care Providers Spot Skin Cancerhttps://practicaldermatology.com/news/dermasensors-skin-cancer-device-may-help-internists-spot-skin-cancer/2461703/DermaSensor Inc.’s nove
- Robert Ryan of Scioderm Appointed Member of DebRA Boardhttps://practicaldermatology.com/news/20131021-robert_ryan_of_scioderm_appointed_member_of_debra_board/2459434/Scioderm, Inc.'s co-founder and CEO Robert
- NKTR-358 Demonstrates Proof of Concept in ADhttps://practicaldermatology.com/news/nktr-358-demonstrates-proof-of-concept-in-ad/2461011/Nektar Therapeutics and its partner Eli Lilly & Company’s NKTR-358 (LY3471851), a novel T regulatory (Treg) cell stimulator, demonstrated proof of concept in a Phase 1b study of patients with moderate-to-severe atopic dermatitis. The findings were presented at Eli Lilly&n
- ASA Honors Outstanding Researchershttps://practicaldermatology.com/news/asa-honors-outstanding-researchers/2460029/Luis Diaz, MD of the University of North Carolina, Chapel Hill and John Stanley, MD of the University of Pennsylvania took home the American Skin Association’s David Martin Carter Mentor Award at the Annual Meeting of t
- Allergan Bolsters Medical Derm Portfolio with Vitae Acquisitionhttps://practicaldermatology.com/news/allergan-to-acquire-vitae-pharmaceuticals/2458435/Allergan plc is acquiring Vitae Pharmaceuticals, Inc., a clinical-stage biotechnology company. The move will serve to bolster Allergan’s medical dermatology pipeline, with the addition of VTP-43742, a Phase 2 first-in-class, orally active ROR?t (retin
- Novan: First Patient Dosed in Phase 2 Anti-Fungal Programhttps://practicaldermatology.com/news/nolan-first-patient-dosed-in-phase-2-anti-fungal-program/2458492/The first patient has been dosed in Novan's clinical program to evaluate the efficacy and safety of topical nitric oxide product candidate SB208 in the treatment of infections caused by dermatophytes such as Trichophyton rubrum (“T. rubrum”). Novan is developing
- Vitae Achieves Proof-of-Concept with First-in-Class RORyt Inhibitor for Psoriasishttps://practicaldermatology.com/news/vitae-achieves-proof-of-concept-with-first-in-class-roryt-inhibitor-for-psoriasis/2458643/Vitae Pharmaceuticals, Inc. shared positive top-line results from its Phase 2a proof-of-concept clinical trial of VTP-43742 in psoriatic patients. VTP-43742 is Vitae's wholly owned, first-in-class, orally active RORγt inhibitor with the potential to transform the treatment of multiple a